SUDEEP PHARMA LIMITED SUDEEPPHRM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.sudeeppharma.com

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceuticals, nutraceutical and nutrition products, food ingredients, mineral and vitamin blends, or premixes for infant, human and animal nutrition, and other chemical and healthcare products. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.

Market & Price

Market Cap

₹8,382.48 Cr

Current Price

₹742.15

High / Low (52W)

₹774.15 / ₹530.00

Beta

Valuation

Stock P/E

49.74

Industry PE

37.60

Forward P/E

38.35

PEG Ratio

Book Value

₹66.50

Price to Book

11.16

P/S

12.50

EV/EBITDA

33.26

Dividend Yield

Profitability & Returns

ROCE

34.57%

ROE

25.06%

ROA

15.57%

Profit Margin

25.77%

Op Margin

32.20%

EPS (Latest Qtr)

₹4.29

EPS (TTM)

₹14.92

Balance Sheet & Liquidity

Debt/Equity

0.17

Quick Ratio

1.69

Current Ratio

3.09

Debt

₹150.42 Cr

Total Assets

₹717.17 Cr

Current Assets

₹424.12 Cr

Working Capital

₹249.36 Cr

Ownership

Promoter Holding

85.61%

Chg in Prom Hold

FII / Inst Holding

7.96%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹8,332.21 Cr

Total Revenue (TTM)

₹670.84 Cr

EBITDA

₹250.49 Cr

Free Cash Flow

₹-89.19 Cr

Operating Cash Flow

₹69.55 Cr

Shares Outstanding

₹11.29 Cr

Gross Margin

66.12%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

8.03%

Profit 5Y

49.18%

Revenue (YoY)

15.70%

Earnings (YoY)

7.60%

PROS

Strong return on equity of 25.1%.
Healthy ROCE of 34.6%.
Excellent profit margin of 25.8%.
Profit CAGR of 49.2% over 5 years.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SUDEEPPHRM SUDEEP PHARMA LIMITED NSEPHARMA	742.15	49.74	₹8,382.48 Cr	-	34.57%	25.06%	8.03%	49.18%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Dec 2025
Revenue	115.54 Cr	152.96 Cr	124.19 Cr	172.34 Cr
Cost of Revenue	37.94 Cr	67.23 Cr	43.81 Cr	60.19 Cr
Gross Profit	77.60 Cr	85.72 Cr	80.38 Cr	112.14 Cr
Operating Expenses	40.96 Cr	28.17 Cr	39.44 Cr	56.03 Cr
Operating Income	36.63 Cr	57.55 Cr	40.94 Cr	56.11 Cr
EBITDA	41.73 Cr	61.35 Cr	48.53 Cr	66.81 Cr
Interest Expense	1.41 Cr	66.52 L	1.21 Cr	1.17 Cr
Pretax Income	37.66 Cr	57.85 Cr	44.07 Cr	61.78 Cr
Tax Provision	8.94 Cr	13.71 Cr	12.80 Cr	14.08 Cr
Net Income	28.71 Cr	44.15 Cr	30.81 Cr	47.46 Cr
Diluted EPS	2.54	-	2.73	4.29

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025
Revenue	426.17 Cr	454.67 Cr	497.41 Cr
Cost of Revenue	188.80 Cr	172.30 Cr	172.26 Cr
Gross Profit	237.37 Cr	282.36 Cr	325.15 Cr
Operating Expenses	153.44 Cr	108.16 Cr	144.19 Cr
Operating Income	83.93 Cr	174.21 Cr	180.96 Cr
EBITDA	97.30 Cr	186.90 Cr	198.09 Cr
Interest Expense	3.41 Cr	3.06 Cr	4.66 Cr
Pretax Income	85.98 Cr	174.82 Cr	182.84 Cr
Tax Provision	23.66 Cr	41.63 Cr	44.15 Cr
Net Income	62.32 Cr	133.19 Cr	138.69 Cr
Diluted EPS	5.52	11.79	12.28

Compounded Sales Growth

5 Years:	8.03%
1 Year:	15.70%

Compounded Profit Growth

5 Years:	49.18%
1 Year:	7.60%

Stock Price Performance

1 Year:	-4.13%
6 Months:	-
3 Months:	+17.50%
1 Month:	+7.12%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025
Total Assets	420.11 Cr	513.87 Cr	717.17 Cr
Current Assets	230.02 Cr	275.37 Cr	424.12 Cr
Cash & Equivalents	10.30 Cr	13.98 Cr	36.81 Cr
Inventory	71.00 Cr	66.58 Cr	128.67 Cr
Receivables	93.71 Cr	144.57 Cr	185.35 Cr
Total Liabilities	196.83 Cr	157.83 Cr	224.08 Cr
Current Liabilities	170.83 Cr	137.22 Cr	174.76 Cr
Long Term Debt	19.94 Cr	11.14 Cr	39.55 Cr
Total Debt	83.08 Cr	78.08 Cr	137.55 Cr
Total Equity	223.28 Cr	356.03 Cr	493.09 Cr
Shares Outstanding	11.29 Cr	11.29 Cr	11.29 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	48.40 Cr	65.69 Cr	48.73 Cr
Investing Cash Flow	-50.02 Cr	-49.28 Cr	-78.76 Cr
Financing Cash Flow	-9.78 Cr	-12.73 Cr	52.70 Cr
Capital Expenditure	-47.15 Cr	-52.46 Cr	-64.23 Cr
Free Cash Flow	1.24 Cr	13.22 Cr	-15.51 Cr
Net Change in Cash	-11.40 Cr	3.67 Cr	22.67 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	55.7%	62.1%	65.4%
Operating Margin %	19.7%	38.3%	36.4%
Net Margin %	14.6%	29.3%	27.9%
ROE %	27.9%	37.4%	28.1%
ROCE %	33.7%	46.3%	33.4%

Shareholding Pattern

Insiders

85.61%

Institutions

7.96%

Public Float

55.36%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SUDEEPPHRM

No recent headlines available.

SUDEEPPHRM · Healthcare